Inhalation Sciences Sweden AB

Equities

ISAB

SE0009983893

Advanced Medical Equipment & Technology

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-01-30 pm EST			5-day change	1st Jan Change
4.34 ^SEK	+6.90%		-.--%	+7.43%

Feb. 28	Inhalation Sciences Sweden AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
Feb. 28	Inhalation Sciences Sweden AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Komplettering till ISAB:s bokslutskommuniké 2023

April 05, 2024 at 07:06 am EDT

Komplettering till ISAB:s bokslutskommuniké 2023

I ISAB's bokslutskommuniké för 2023 publicerad den 28e februari 2024, har intäkten från Aprinha projektet redovisats som nettoomsättning. Det gäller intäkter på totalt 642 tkr för 2023.

Då denna intäkt förmedlats via Vinnova, så behöver den omklassificeras från "omsättning" till "övriga rörelseintäkter". Detta innebär att den redovisade nettoomsättningen i bokslutskommunikén behöver justeras från 18 146 tkr till 17 504 tkr och samtidigt 642 tkr tillskrivas i posten "övriga rörelseinkomster"

Denna Omklassificering påverkar inte bolagets resultat, finansiella ställning eller kassaflöde.

För mer information om Inhalation Sciences, vänligen kontakta: Manoush Masarrat, VD E-post: Manoush.masarrat@inhalation.se Telefon: +46 (0)73 628 9153

Press release in PDF format

Attachments

Original Link
Permalink

Disclaimer

Inhalation Sciences Sweden AB published this content on 05 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 April 2024 11:05:04 UTC.

Latest news about Inhalation Sciences Sweden AB

Inhalation Sciences Sweden AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Inhalation Sciences Sweden AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Inhalation Sciences Signs New Partnership with Actarmo Medical	Jan. 22	CI
Inhalation Sciences AB Secures Product Service Contract Worth EUR 47,000	Dec. 29	CI
Inhalation Sciences Sweden AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 22	CI
Inhalation Sciences Secures New Purchase Order Worth EUR 276,450	Nov. 13	CI
Inhalation Sciences Sweden AB Secures New Order Worth 54,700 Euro	Nov. 08	CI
Inhalation Sciences Secures EUR 188,900 Order from Top-Five Global Generics Manufacturer	23-10-16	CI
Inhalation Sciences Signs Collaboration Agreement with Leading Indian Multinational Pharma Company	23-09-29	CI
Inhalation Sciences Sweden AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29	CI
Inhalation Sciences Wins New Purchase Order from Asian Distributor Worth USD 94,000	23-06-28	CI
Inhalation Sciences Receives Purchase Order Worth 125.8 KEURO from International Distributor for Asia	23-06-27	CI
Inhalation Research Services Wins New Order Worth 98,000 from Returning US Customer	23-06-21	CI
Inhalation Sciences Sweden AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-31	CI
Inhalation Sciences Receives New Order Worth 53,000 from Return Customer	23-05-22	CI
Inhalation Sciences Receives Formal Clearance to Begin the Trial of Inhalation Study	23-05-05	CI
Inhalation Sciences AB Receives IRS Order Worth EUR 35,000 from Global Generics Company	23-03-21	CI
Inhalation Sciences Sweden AB Receives IRS Order Worth EUR 118,464 from Us Client Following EUR 50,000 Deposit	23-03-07	CI
Inhalation Sciences Sweden AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-28	CI
Inhalation Sciences Sweden AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
Inhalation Sciences Sweden AB Receives IRS Order Worth over SEK 914,000 from New US Pharma Customer	23-01-31	CI
Inhalation Sciences Signs R&D Order Worth 257,000 SEK with Major Generic Pharma Company	22-12-23	CI
Inhalation Sciences AB Receives IRS Order Worth SEK 1.9 Million with US Pharma Company	22-12-23	CI
Inhalation Sciences Sweden AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-22	CI
Inhalation Sciences Begins Planned FDA BAA Dissolution Research Project	22-11-14	CI

Chart Inhalation Sciences Sweden AB

Duration

Period

More charts

Company Profile

Inhalation Sciences Sweden AB is a Sweden-based company, which develops and sells labtech equipment for inhalation research. The Companyâs primary product is PreciseInhale, which is a laboratory system that lets scientists measure how inhaled particles act in lungs and affect human health. PreciseInhale is a dry powder aerosol research and development system, which generate aerosols and data of a quality. The system helps to eliminate poor candidate drugs before clinical trials. The secondary product is LaminarPace, a tool for drying small amounts of drug substance. The Companyâs customers comprise Dow Chemical Group, Kings College London and Karolinska Institutet, among others. The Companyâs main shareholder is Nordnet Pensionsforsakring.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
INHALATION SCIENCES SWEDEN AB	+7.43%	6.04M
THERMO FISHER SCIENTIFIC	+7.84%	218B
DANAHER CORPORATION	+7.35%	183B
INTUITIVE SURGICAL, INC.	+13.04%	134B
BOSTON SCIENTIFIC CORPORATION	+26.03%	106B
SIEMENS HEALTHINEERS AG	-1.33%	61.12B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.81%	50.89B
AGILENT TECHNOLOGIES, INC.	+0.30%	40.3B
GE HEALTHCARE TECHNOLOGIES INC.	+2.78%	35.53B
RESMED, INC.	+26.14%	32.05B

Other Advanced Medical Equipment & Technology